P-CABs-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication

Bismuth-containing quadruple therapy was recommended as a first-line treatment for Helicobacter pylori infection. This study aimed to compare real-world outcomes of various potassium-competitive acid blockers (P-CABs) -based bismuth quadruple regimens and identify factors influencing treatment failure. A multicenter cohort study was conducted and study outcomes included eradication rates and incidence of adverse events.

NCT Number	NCT07285096
Lead Sponsor	Yueyue Li Collaborators: Qilu Hospital of Shandong University, Feicheng People's Hospital, Binzhou Maternal and Child Health Hospital, Jinxiang County People's Hospital, The People's Hospital of Jimo, Zibo Maternal and Child Health Hospital, Yantai Penglai Traditional Chinese Medicine Hospital, Zaozhuang Municipal Hospital, Linyi Yizhou Hospital, Taierzhuang District People's Hospital, Shandong University of Traditional Chinese Medicine, Yuncheng Traditional Chinese Medicine Hospital, Caoxian County Hospital, Qihe County People's Hospital, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Dezhou Hospital Qilu Hospital of Shandong University, Dongying No. 2 People's Hospital, Zhangdian District Hospital of Traditional Chinese Medicine, Yantai Zhifu Hospital, Inner Mongolia People's Hospital, Hohhot Second Hospital, Guanxian County People's Hospital, Longkou People's Hospital, Linshu County Hospital of Traditional Chinese Medicine
Conditions	Helicobacter Pylori Infection
Enrollment	1,730 participants
Start Date	2025-12-16
Primary Completion	2026-06-01 (estimated)
Study Completion	2026-08-01 (estimated)
Updated on ClinicalTrials.gov	2025-12-23